Vaccitech acquires Avidea Technologies to expand product pipeline and strengthen scientific leadership in immunotherapies and vaccines

Avidea CEO to present updates on SNAPvax programs at the Vaccines R&D meeting in Baltimore on November 2nd and at the Festival of Biologics in Basel, Switzerland on November 10th.

Avidea Expands Scientific Advisory Board with Appointment of Prof. Dan Barouch, MD, PhD

Avidea’s SNAPvax^TM Tolerance Vaccine Program Boosted by SAB Appointments and Encouraging Preclinical Data

Avidea Technologies and University of Maryland Awarded Grant to Evaluate Avidea’s SNAPvax^TM Tolerance Vaccine (TV) for Treating Autoimmune Diseases

Avidea to present at World Immunotherapy Congress on March 29th and NeoAg Summit on April 21st.

Avidea Technologies and Collaborators Publish Results in Nature Immunology Showing SNAPvax^TM Cancer Vaccine Administered IV Generates Stem-Like (TCF1⁺) Neoantigen-Sepcific CD8⁺ T cells Resulting in Improved Efficacy

Intravenous nanoparticle vaccination generates stem-like TCF1+ neoantigen-specific CD8+ T cells

Nature Biotechnology features Avidea’s self-assembling nanoparticle technology, SNAPvax (SNP-7/8a) on the Cover of its March 2020 issue

Peptide–TLR-7/8a conjugate vaccines chemically programmed for nanoparticle self-assembly enhance CD8 T-cell immunity to tumor antigens

Avidea is accepted into the Nanoparticle Characterization Lab at the Frederick National Laboratory for Cancer Research, sponsored by the National Cancer Institute

Avidea co-authors publication on combining therapeutic cancer vaccines with oncolytic virotherapy

Oncolytic herpes simplex virus immunotherapy for brain tumors: current pitfalls and emerging strategies to overcome therapeutic resistance

Avidea co-authors publication on Star nanoparticles as an HIV vaccine in PLOS Biology

Star nanoparticles delivering HIV-1 peptide minimal immunogens elicit near-native envelope antibody responses in nonhuman primates

Avidea co-authors publication on intravenously administered nanomedicines for enhanced cancer immunotherapy in Cancer Letters

Induction of anti-cancer T cell immunity by in situ vaccination using systemically administered nanomedicines

Avidea co-founder and CEO named Top 10 CEO in Baltimore biotech start up scene

Avidea co-authors publication on polymer-TLR-7/8 agonist compositions for inducing CD8 T cell responses in ACS journal Biomacromolecules

Impact of Polymer-TLR-7/8 Agonist (Adjuvant) Morphology on the Potency and Mechanism of CD8 T Cell Induction

Darrell Irvine, MIT Professor of Materials Science and Engineering, writes that Avidea’s technology linking TLR agonists to polymers is a “promising approach” to vaccine development in Nature Materials.

Material aid for vaccines

Avidea co-founder profiled by Johns Hopkins Technology Ventures

The National Institute of Allergy and Infectious Diseases (NIAID) and Avidea Technologies (Avidea) have entered into an agreement to evaluate the therapeutic potential of Avidea’s polymer-based vaccine technology, “Immunotherapeutic Nanoscaffolds” (IMNs), including Star polymers and self-assembling nanoparticles based on amphiphilic polymers (SNAP), in preclinical animal models for cancer, infectious and inflammatory diseases.

Avidea obtains exclusive rights to the immunotherapeutics delivery technology PolyMAP from PsiOxus Therapeutics